699002-91-0

Basic information

• Product Name: 1-(5-O-trityl-2-deoxy-β-D-lyxofuranosyl)-5-iodoracil
• Synonyms: 1-(5-O-trityl-2-deoxy-β-D-lyxofuranosyl)-5-iodoracil
• CAS NO: 699002-91-0
• Molecular Weight: 596.421
• Mol File: 699002-91-0.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 1-(5-O-trityl-2-deoxy-β-D-lyxofuranosyl)-5-iodoracil(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(5-O-trityl-2-deoxy-β-D-lyxofuranosyl)-5-iodoracil(699002-91-0)
• EPA Substance Registry System: 1-(5-O-trityl-2-deoxy-β-D-lyxofuranosyl)-5-iodoracil(699002-91-0)

Safety Data

• Hazardous Substances Data: 699002-91-0(Hazardous Substances Data)

Upstream product

• 54-42-2 5-Iodo-2'-deoxyuridine 
• 76-83-5 trityl chloride 
• 15414-61-6 2'-deoxy-5-iodo-5'-O-(triphenylmethyl)uridine 
• 101039-82-1 5-iodo-3'-O-mesyl-5'-O-trityl-2'-deoxyuridine 

Downstream Products

• 1216453-66-5 C₃₁H₂₇FN₂O₄ 
• 162239-35-2 1-(2-deoxy-β-D-lyxofuranosyl)-5-iodouracil 
• 1037303-83-5 C₃₁H₂₈N₂O₅ 
• 119644-23-4 5-iodo-2',3'-dideoxy-3'-fluorouridine 
• 699002-92-1 1-((2R,4S,5R)-4-Fluoro-5-trityloxymethyl-tetrahydro-furan-2-yl)-5-iodo-1H-pyrimidine-2,4-dione 

Relevant articles and documents

Synthesis and Antiviral Evaluation of Some 3′-Fluoro Bicyclic Nucleoside Analogues

The synthesis of 3′-fluoro analogues of recently discovered highly potent anti-VZV furanopyrimidine deoxynucleosides (BCNAs) is herein reported, for both the alkyl and alkylphenyl series. The compounds are tested against a range of herpes viruses and disp

Antiviral activity of various 1-(2′-Deoxy-β- d -lyxofuranosyl), 1-(2′-Fluoro-β- d -xylofuranosyl), 1-(3′-Fluoro-β- d -arabinofuranosyl), and 2′-fluoro-2′,3′-didehydro-2′, 3′-dideoxyribose pyrimidine nucleoside analogues against duck hepatitis B virus (DHBV) and human hepatitis B virus (HBV) replication

Despite the existence of successful vaccine and antiviral therapies, infection with hepatitis B virus (HBV) continues to be a major global cause of acute and chronic liver disease and high mortality. We synthesized and evaluated several lyxofuranosyl, 2′-fluoroxylofuranosyl, 3′- fluoroarabinofuranosyl, and 2′-fluoro-2′,3′-didehydro- 2′,3′-dideoxyribose pyrimidine nucleoside analogues for antiviral activities against hepatitis B virus. Among the compounds examined, 1-(2-deoxy-β-d-lyxofuranosyl)thymine (23), 1-(2-deoxy-β-d- lyxofuranosyl)-5-trifluoromethyluracil (25), 1-(2-deoxy-2-fluoro-β-d- xylofuranosyl)uracil (38), 1-(2-deoxy-2-fluoro-β-d-xylofuranosyl)thymine (39), 2′,3′-dideoxy-2′,3′-didehydro-2′- fluorothymidine (48), and 2′,3′-dideoxy-2′,3′-didehydro- 2′-fluoro-5-ethyluridine (49) were found to possess significant anti-HBV activity against DHBV in primary duck hepatocytes with EC50 values of 4.1, 3.3, 40.6, 3.8, 0.2, and 39.0 μM, respectively. Compounds 23, 25, 39, 48, and 49 (EC50 = 41.3, 33.7, 19.2, 2.0-4.1, and 39.0 μM, respectively) exhibited significant activity against wild-type human HBV in 2.2.15 cells. Intriguingly, 25, 39, 48, and 49 retained sensitivity against lamivudine-resistant HBV containing a single mutation (M204I) and 48 emerged as an effective inhibitor of drug-resistant HBV with an EC50 of 4.1 μM. In contrast, 50% inhibition could not be achieved by lamivudine at 44 μM concentration in the drug-resistant strain. The compounds investigated did not show cytotoxicity to host cells up to the highest concentrations tested.